NinePointTwo Capital’s BridgeBio Pharma BBIO Stock Holding History

NinePointTwo Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$340K	Hold	8,442	–	–	0.14%	93
2023 Q3	$222K	Sell	8,442 -4,601	-35%	-$131K	0.09%	182
2023 Q2	$224K	Hold	13,043	–	–	0.09%	182
2023 Q1	$216K	Sell	13,043 -2,513	-16%	-$29.3K	0.08%	196
2022 Q4	$118K	Sell	15,556 -15,745	-50%	-$151K	0.05%	173
2022 Q3	$311K	Buy	+31,301	New	+$325K	0.13%	92

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NinePointTwo Capital's BBIO Position: Q4 2023 in Review

NinePointTwo Capital held its BridgeBio Pharma (BBIO) position steady in Q4 2023 at 8,442 shares worth $340K. The position accounts for 0.14% of the portfolio, ranked #93.

NinePointTwo Capital first reported a position in BBIO in Q3 2022 and has held it in 6 quarters since. 247 funds tracked by Wall St. Rank hold BBIO as of Q4 2023.

NinePointTwo Capital held 8,442 shares of BridgeBio Pharma worth $340K as of Q4 2023.
NinePointTwo Capital left its BridgeBio Pharma share count unchanged in Q4 2023.
BridgeBio Pharma made up 0.14% of NinePointTwo Capital's portfolio in Q4 2023, its #93 holding.
NinePointTwo Capital first reported a position in BridgeBio Pharma in Q3 2022 and has held it in 6 quarters since.
247 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.